Cerebrolysin
Also known as: FPF 1070
Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins, consisting of low-molecular-weight peptides and free amino acids that mimic the action of endogenous neurotrophic factors.
Key Findings at a Glance
- •A meta-analysis of nine randomized trials including 1,879 stroke patients demonstrated Cerebrolysin superiority on NIHSS at day 30 with a number needed to treat of 7.7 for early neurological improvement.
- •In Alzheimer's disease, pooled analysis of six placebo-controlled trials showed significant cognitive improvement with standardized mean difference of -0.40 and odds ratio of 4.98 for global clinical change at 6 months.
- •Cerebrolysin is registered in over 50 countries and has been used clinically for more than 50 years for neurological conditions, though it is not FDA-approved in the United States.
- •The low-molecular-weight peptide fraction (below 10 kDa) crosses the blood-brain barrier and mimics the actions of BDNF, NGF, and GDNF, providing multimodal neurotrophic support that recombinant proteins cannot achieve due to their large molecular size.
Cerebrolysin Overview & Molecular Profile
Cerebrolysin (FPF 1070) is a unique neuropeptide preparation produced by standardized enzymatic proteolysis of purified porcine brain proteins, yielding a mixture of approximately 85% free amino acids and 15% low-molecular-weight peptides (below 10 kDa). Developed and manufactured by EVER Neuro Pharma, this preparation has been used clinically for over 50 years, primarily in Europe, Russia, China, and other Asian countries, for neurological conditions including acute ischemic stroke, traumatic brain injury, and Alzheimer's disease. The peptide components of Cerebrolysin mimic the biological actions of naturally occurring neurotrophic factors including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF), but with the advantage of being able to cross the blood-brain barrier due to their small molecular size. Although Cerebrolysin is not approved by the FDA in the United States, it is registered in over 50 countries and has been the subject of numerous randomized controlled trials and meta-analyses evaluating its neuroprotective and neuroregenerative properties.
Mechanism of Action: Neuroprotection & Synaptic Plasticity
Cerebrolysin exerts its effects through a multimodal mechanism that recapitulates the actions of endogenous neurotrophic factors. The low-molecular-weight peptide fraction crosses the blood-brain barrier and activates intracellular signaling cascades involved in neuronal survival, differentiation, and synaptic plasticity. Key mechanisms include activation of the PI3K/Akt survival pathway, which inhibits apoptotic neuronal death, and modulation of the MAPK/ERK signaling cascade, which promotes neuronal differentiation and neurite outgrowth. Cerebrolysin has been shown to modulate the expression of endogenous neurotrophic factors including BDNF, NGF, and VEGF, amplifying intrinsic neuroprotective mechanisms. Additional neuroprotective effects include reduction of excitotoxic damage through modulation of glutamate receptor activity, antioxidant effects through hydroxyl radical scavenging, and anti-inflammatory actions through inhibition of microglial activation and pro-inflammatory cytokine release. The preparation also promotes neurogenesis in the hippocampal dentate gyrus and subventricular zone, supports dendritic arborization, and enhances long-term potentiation, the cellular substrate of learning and memory.
Research-Observed Effects
Neuroprotection in Acute Stroke
Multiple randomized controlled trials have evaluated Cerebrolysin in acute ischemic stroke, with mixed but generally promising results. The CASTA trial (Cerebrolysin in Patients with Acute Ischemic Stroke in Asia) enrolled 1,070 patients and found favorable trends in severely affected subgroups, though the primary composite endpoint did not reach significance. A meta-analysis of nine randomized clinical trials encompassing 1,879 patients demonstrated superiority of Cerebrolysin on NIHSS scores at day 30 with a number needed to treat of 7.7 for early neurological improvement. A separate safety meta-analysis of 12 RCTs including 2,202 patients confirmed that Cerebrolysin's safety profile is comparable to placebo. The neuroprotective effects are attributed to reduction of infarct volume through anti-excitotoxic and anti-apoptotic mechanisms, preservation of penumbral tissue, and promotion of early neuroplastic recovery.
Cognitive Enhancement in Alzheimer's Disease
A meta-analysis of six randomized, double-blind, placebo-controlled trials in mild-to-moderate Alzheimer's disease demonstrated significant improvements in cognitive function with Cerebrolysin 30 mL daily. The pooled analysis showed a standardized mean difference of -0.40 for cognitive function at 4 weeks and an odds ratio of 4.98 for global clinical improvement at 6 months compared to placebo. Individual trials have documented improvements on the Mini-Mental State Examination, the ADAS-Cog scale, and measures of activities of daily living. The cognitive benefits are attributed to enhancement of cholinergic neurotransmission, promotion of hippocampal neurogenesis, and modulation of amyloid precursor protein processing. A 30-year review of clinical use confirmed a favorable benefit-risk ratio in mild-to-moderate Alzheimer's disease.
Traumatic Brain Injury Recovery
Clinical studies have evaluated Cerebrolysin for traumatic brain injury (TBI) recovery, demonstrating potential benefits in cognitive and functional outcomes. The neurotrophic factor-like activity of Cerebrolysin supports repair processes following traumatic injury including reduction of cerebral edema, attenuation of secondary injury cascades, and promotion of axonal regeneration. Studies have documented improvements in Glasgow Outcome Scale scores and cognitive test performance in TBI patients treated with Cerebrolysin compared to standard care alone. The multi-target mechanism addressing excitotoxicity, oxidative stress, and neuroinflammation simultaneously may be particularly relevant in TBI where multiple pathological cascades are activated concurrently.
Vascular Dementia Treatment
A Cochrane systematic review of six randomized controlled trials including 597 participants evaluated Cerebrolysin for vascular dementia. The review found possible improvement in cognitive function, though the authors noted that further high-quality research is needed to confirm these findings. The rationale for Cerebrolysin use in vascular dementia includes promotion of angiogenesis in ischemic brain regions, neuroprotection against chronic hypoperfusion-induced damage, and enhancement of synaptic plasticity in surviving neurons. The combination of neurotrophic support and vascular effects may be particularly suited to vascular dementia where both neuronal damage and cerebrovascular insufficiency contribute to cognitive decline.
Neuroplasticity and Neurogenesis Promotion
Preclinical studies have consistently demonstrated that Cerebrolysin promotes structural and functional neuroplasticity through multiple mechanisms. These include stimulation of adult neurogenesis in the hippocampal dentate gyrus and subventricular zone, enhancement of dendritic branching and spine density, promotion of long-term potentiation at glutamatergic synapses, and modulation of synaptic vesicle recycling. The effects on neuroplasticity are mediated through upregulation of BDNF, activation of TrkB receptor signaling, and enhancement of CREB-dependent gene transcription. These mechanisms provide the neurobiological basis for observed clinical improvements in cognitive function and functional recovery across multiple neurological conditions.
Research Dosing Information
In clinical trials, Cerebrolysin is typically administered as an intravenous infusion at doses of 10-30 mL daily for treatment courses of 10-20 days. For Alzheimer's disease, the standard protocol is 30 mL diluted in saline administered as a 30-minute infusion, 5 days per week for 4 weeks. Treatment courses may be repeated after washout periods. Lower doses of 5-10 mL may be administered intramuscularly.
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial
Heiss WD, Brainin M, Bornstein NM, et al. (2012). Stroke
The CASTA trial was a large-scale, double-blind, placebo-controlled randomized trial evaluating Cerebrolysin in 1,070 patients with acute ischemic stroke across multiple Asian centers. Participants received either Cerebrolysin 30 mL or placebo intravenously daily for 10 days, initiated within 12 hours of symptom onset. The primary endpoint was a global statistical test combining the modified Rankin Scale, Barthel Index, and NIHSS at day 90. While the primary composite endpoint did not reach statistical significance in the overall population, pre-specified subgroup analyses revealed favorable trends in patients with more severe strokes (NIHSS greater than 12 at baseline). Safety analysis demonstrated that Cerebrolysin was well tolerated with an adverse event profile comparable to placebo. The trial provided important data on the safety of early Cerebrolysin administration in acute stroke and identified severely affected patients as a potential target population for future trials.
Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials
Bornstein NM, Guekht A, Vester J, et al. (2018). Neurological Sciences
This comprehensive meta-analysis pooled data from nine randomized clinical trials encompassing 1,879 patients to evaluate the efficacy and safety of Cerebrolysin in early post-stroke recovery. The primary analysis demonstrated superiority of Cerebrolysin over placebo on NIHSS improvement at day 30, with a Mann-Whitney effect size of 0.60 that was highly statistically significant. The number needed to treat for early NIHSS improvement was calculated at 7.7, indicating clinically meaningful benefit. In patients with moderate-to-severe stroke, Cerebrolysin showed significant improvement on the modified Rankin Scale at day 90. Safety analysis confirmed that the incidence of adverse events, serious adverse events, and mortality was comparable between Cerebrolysin and placebo groups. The meta-analysis addressed limitations of individual trials by achieving adequate statistical power through data pooling and confirmed consistent treatment effects across diverse patient populations and trial designs.
Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials
Gauthier S, Bhatt DL, Gong J, et al. (2015). Dementia and Geriatric Cognitive Disorders
This meta-analysis synthesized results from six randomized, double-blind, placebo-controlled trials evaluating Cerebrolysin 30 mL daily in patients with mild-to-moderate Alzheimer's disease. The pooled analysis demonstrated statistically significant improvements in cognitive function at 4 weeks with a standardized mean difference of -0.40 favoring Cerebrolysin over placebo. Global clinical change outcomes showed odds ratios of 3.32 at 4 weeks and 4.98 at 6 months, both statistically significant and clinically meaningful. Safety analysis confirmed that the incidence of adverse events with Cerebrolysin was comparable to placebo, with no signal for cardiovascular, hepatic, or other organ toxicity. The magnitude of cognitive benefit was modest but consistent across trials and comparable to the effects reported with cholinesterase inhibitors in similar populations. The authors concluded that Cerebrolysin demonstrates a favorable benefit-risk ratio in mild-to-moderate Alzheimer's disease and merits consideration as an adjunctive or alternative neurotrophic therapy.
Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin
Sharma HS, Muresanu DF, Lafuente JV, et al. (2023). Progress in Brain Research
This comprehensive review examined the neurotrophic factor modulation mechanisms underlying Cerebrolysin's clinical effects across dementia, stroke, and traumatic brain injury. The authors synthesized preclinical and clinical evidence demonstrating that Cerebrolysin mimics the actions of endogenous neurotrophic factors including NGF, BDNF, IGF-1, and VEGF while simultaneously modulating their endogenous expression. Key mechanisms reviewed include promotion of neuroplasticity through CREB-dependent gene transcription, enhancement of neurogenesis in the hippocampal dentate gyrus, angiogenesis promotion in ischemic brain tissue, and anti-inflammatory effects through microglial phenotype modulation. The review highlighted Cerebrolysin's unique ability to cross the blood-brain barrier as a critical advantage over recombinant neurotrophic factors, which are too large for brain penetration. Evidence from clinical trials was integrated with preclinical mechanistic data to present a unified framework for understanding Cerebrolysin's multimodal neuroprotective activity. The authors concluded that the multi-target neurotrophic approach may be inherently better suited to complex neurological conditions than single-target therapies.
Frequently Asked Questions
Semax
C37H51N9O10S
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH). It was developed in Russia as a nootropic and neuroprotective agent with applications in cognitive enhancement research.
Selank
C33H57N11O9
Selank is a synthetic peptide analog of the endogenous tetrapeptide tuftsin. It was developed in Russia for its anxiolytic and nootropic properties and has been studied for effects on stress response and cognitive function.
Dihexa
C27H44N4O5
Dihexa is a synthetic peptide derivative of angiotensin IV that has been studied for potent nootropic and neuroprotective effects. It is reported to be extremely potent in promoting cognitive function.